Microglia, Alzheimer's disease, and complement
Helen Crehan1, John Hardy, Jennifer Pocock
1Department of Molecular Neurosciences, University College London Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK.
Abstract:
Microglia, the immune cell of the brain, are implicated in cascades leading to neuronal loss and cognitive decline in Alzheimer's disease (AD). Recent genome-wide association studies have indicated a number of risk factors for the development of late-onset AD. Two of these risk factors are an altered immune response and polymorphisms in complement receptor 1. In view of these findings, we discuss how complement signalling in the AD brain and microglial responses in AD intersect. Dysregulation of the complement cascade, either by changes in receptor expression, enhanced activation of different complement pathways or imbalances between complement factor production and complement cascade inhibitors may all contribute to the involvement of complement in AD. Altered complement signalling may reduce the ability of microglia to phagocytose apoptotic cells and clear amyloid beta peptides, modulate the expression by microglia of complement components and receptors, promote complement factor production by plaque-associated cytokines derived from activated microglia and astrocytes, and disrupt complement inhibitor production. The evidence presented here indicates that microglia in AD are influenced by complement factors to adopt protective or harmful phenotypes and the challenge ahead lies in understanding how this can be manipulated to therapeutic advantage to treat late onset AD.
Insights
Microglia, the brain's immune cells, interact with complement signaling in Alzheimer's disease (AD). Understanding this relationship is key to developing new AD therapies.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Microglia are brain immune cells implicated in neuronal loss and cognitive decline in Alzheimer's disease (AD).
- Genome-wide association studies identify altered immune response and complement receptor 1 (CR1) gene variations as risk factors for late-onset AD.
- Complement signaling plays a crucial role in neuroinflammation and AD pathogenesis.
Purpose of the Study:
- To discuss the intersection of complement signaling and microglial responses in the context of Alzheimer's disease.
- To explore how dysregulation of the complement cascade contributes to AD.
- To investigate the impact of complement factors on microglial phenotypes in AD.
Main Methods:
- Review and synthesis of existing literature on microglia, complement system, and Alzheimer's disease.
- Analysis of findings from genome-wide association studies related to AD risk factors.
- Discussion of the molecular mechanisms linking complement dysregulation to microglial function.
Main Results:
- Dysregulation of the complement cascade (e.g., altered receptor expression, pathway activation, or factor imbalances) is implicated in AD.
- Altered complement signaling can impair microglial phagocytosis of apoptotic cells and amyloid-beta peptides.
- Complement factors influence microglia to adopt either protective or detrimental phenotypes in AD.
Conclusions:
- The interplay between complement signaling and microglia is a significant factor in Alzheimer's disease.
- Understanding how complement influences microglial phenotypes offers potential therapeutic targets for late-onset AD.
- Further research is needed to harness this interaction for effective AD treatment.
Related Concept Videos
01:27Complement System
01:23Alzheimer Disease ll: Pathophysiology
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
01:22Dementia l: Introduction